RA Capital Management - Q3 2021 holdings

$7.22 Billion is the total value of RA Capital Management's 95 reported holdings in Q3 2021. The portfolio turnover from Q2 2021 to Q3 2021 was 0.0% .

 Value Shares↓ Weighting
FMTX  FORMA THERAPEUTICS HLDGS INC$208,980,000
-6.8%
9,011,6510.0%2.90%
-19.6%
JANX  JANUX THERAPEUTICS INC$187,546,000
-13.3%
8,670,6440.0%2.60%
-25.1%
VOR  VOR BIOPHARMA INC$174,377,000
-15.9%
11,120,9730.0%2.42%
-27.4%
AVTE  AEROVATE THERAPEUTICS INC$173,378,000
-8.1%
8,263,9820.0%2.40%
-20.7%
CNTB  CONNECT BIOPHARMA HLDGS LTDads$169,392,000
+24.1%
6,991,0030.0%2.35%
+7.1%
NKTX  NKARTA INC$155,879,000
-12.2%
5,605,1290.0%2.16%
-24.2%
TVTX  TRAVERE THERAPEUTICS INC$136,150,000
+66.2%
5,614,4280.0%1.89%
+43.5%
MGNX  MACROGENICS INC$124,459,000
-22.0%
5,943,5940.0%1.72%
-32.7%
ITOS  ITEOS THERAPEUTICS INC$119,266,000
+5.3%
4,417,2590.0%1.65%
-9.1%
DAWN  DAY ONE BIOPHARMACEUTICALS I$117,833,000
+4.2%
4,965,5880.0%1.63%
-10.0%
IMGN  IMMUNOGEN INC$104,427,000
-14.0%
18,417,4580.0%1.45%
-25.7%
PHAT  PHATHOM PHARMACEUTICALS INC$99,992,000
-5.2%
3,115,0080.0%1.39%
-18.1%
ETNB  89BIO INC$97,279,000
+4.8%
4,965,7690.0%1.35%
-9.5%
TIL  INSTIL BIO INC$87,065,000
-7.5%
4,870,7930.0%1.21%
-20.1%
KNTE  KINNATE BIOPHARMA INC$82,712,000
-1.1%
3,593,0520.0%1.15%
-14.7%
HOWL  WEREWOLF THERAPEUTICS INC$73,649,000
-1.6%
4,291,8810.0%1.02%
-15.0%
RYTM  RHYTHM PHARMACEUTICALS INC$63,616,000
-10.5%
4,871,0670.0%0.88%
-22.7%
RCKT  ROCKET PHARMACEUTICALS INC COM$62,983,000
-32.5%
2,107,1490.0%0.87%
-41.7%
CCCC  C4 THERAPEUTICS INC$61,550,000
+18.1%
1,377,5690.0%0.85%
+1.9%
OLMA  OLEMA PHARMACEUTICALS INC$59,265,000
-1.5%
2,150,4040.0%0.82%
-15.0%
PMVP  PMV PHARMACEUTICALS INC$50,966,000
-12.8%
1,710,2650.0%0.71%
-24.7%
DYN  DYNE THERAPEUTICS INC$45,554,000
-22.8%
2,805,0450.0%0.63%
-33.4%
GRPH  GRAPHITE BIO INC$44,226,000
-46.7%
2,698,3690.0%0.61%
-53.9%
EWTX  EDGEWISE THERAPEUTICS INC$43,386,000
-22.2%
2,613,6230.0%0.60%
-32.8%
VERV  VERVE THERAPEUTICS INC$41,373,000
-22.0%
880,2840.0%0.57%
-32.7%
GERN  GERON CORP$41,273,000
-2.8%
30,126,2990.0%0.57%
-16.1%
ACHL  ACHILLES THERAPEUTICS PLCsponsored ads$39,064,000
-20.4%
5,014,6870.0%0.54%
-31.3%
WVE  WAVE LIFE SCIENCES LTD$38,099,000
-26.4%
7,775,2070.0%0.53%
-36.5%
KALV  KALVISTA PHARMACEUTICALS INC$33,684,000
-27.2%
1,930,3220.0%0.47%
-37.1%
DSGN  DESIGN THERAPEUTICS INC$32,122,000
-26.1%
2,186,6360.0%0.44%
-36.2%
BOLT  BOLT BIOTHERAPEUTICS INC$30,086,000
-18.2%
2,378,3250.0%0.42%
-29.3%
SLDB  SOLID BIOSCIENCES INC$29,559,000
-34.7%
12,367,8730.0%0.41%
-43.6%
KALA  KALA PHARMACEUTICALS INC$28,491,000
-50.6%
10,874,6130.0%0.40%
-57.3%
VRNA  VERONA PHARMA PLCsponsored ads$27,948,000
-16.2%
5,100,0000.0%0.39%
-27.7%
STSA  SATSUMA PHARMACEUTICALS INC$27,560,000
-33.9%
5,914,2520.0%0.38%
-42.9%
AKUS  AKOUOS INC$26,485,000
-7.5%
2,281,2490.0%0.37%
-20.2%
IPSC  CENTURY THERAPEUTICS INC$22,999,000
-14.2%
914,0940.0%0.32%
-25.8%
BDTX  BLACK DIAMOND THERAPEUTICS INC$21,911,000
-30.6%
2,589,9040.0%0.30%
-40.0%
SCPH  SCPHARMACEUTICALS INC$18,162,000
+8.8%
2,731,1700.0%0.25%
-6.0%
CTMX  CYTOMX THERAPEUTICS INC$17,815,000
-19.6%
3,500,0000.0%0.25%
-30.6%
LRMR  LARIMAR THERAPEUTICS INC$17,470,000
+17.4%
1,515,1510.0%0.24%
+1.3%
SBTX  SILVERBACK THERAPEUTICS INC$17,387,000
-67.7%
1,742,1860.0%0.24%
-72.1%
MIST  MILESTONE PHARMACEUTICALS INC$12,828,000
+3.8%
2,246,5030.0%0.18%
-10.1%
BLSA  BCLS ACQUISITION CORP$12,450,000
-5.4%
1,250,0000.0%0.17%
-18.0%
ENTX  ENTERA BIO LTD$11,083,000
-21.2%
2,353,0000.0%0.15%
-31.9%
FSII  FS DEVELOPMENT CORP II$9,950,000
-0.3%
1,000,0000.0%0.14%
-13.8%
CNCE  CONCERT PHARMACEUTICALS INC$9,920,000
-22.5%
3,033,6030.0%0.14%
-33.2%
FLACU  FRAZIER LIFESCIENCES ACQUISITION CO$9,820,000
-2.3%
1,000,0000.0%0.14%
-15.5%
IKNA  IKENA ONCOLOGY INC$9,465,000
-10.1%
750,0000.0%0.13%
-22.5%
PHAS  PHASEBIO PHARMACEUTICALS INC$8,864,000
-16.4%
2,850,0000.0%0.12%
-27.6%
COGT  COGENT BIOSCIENCES INC$8,626,000
+3.7%
1,025,6410.0%0.12%
-10.4%
CGEM  CULLINAN ONCOLOGY INC$7,900,000
-12.3%
350,0000.0%0.11%
-24.8%
OCUL  OCULAR THERAPEUTIX INC$7,500,000
-29.5%
750,0000.0%0.10%
-39.2%
FVAM  5 01 ACQUISITION CORP$7,365,000
-1.5%
750,0000.0%0.10%
-15.0%
HLXA  HELIX ACQUISITION CORP$6,965,000
-3.9%
700,0000.0%0.10%
-16.4%
HSAQ  HEALTH SCIENCES ACQ CORP 2$6,181,000
-3.0%
625,0000.0%0.09%
-15.7%
BMEA  BIOMEA FUSION INC$5,985,000
-23.3%
500,0000.0%0.08%
-33.6%
CVRX  CVRX INC$4,549,000
-40.9%
275,0000.0%0.06%
-49.2%
SYRS  SYROS PHARMACEUTICALS INC$4,023,000
-18.0%
900,0000.0%0.06%
-29.1%
RPHM  RENEO PHARMACEUTICALS INC$464,000
-20.0%
62,2170.0%0.01%
-33.3%
Original filings

The following EDGAR filing(s) were analyzed to create this report:

  • View 13F-HR filed 2021-11-15
Signatures

The EDGAR filing(s) were signed by:

About RA Capital Management

RA Capital Management is a Boston-based investment management firm that specializes in the healthcare sector. The firm was founded in 2001 by Peter Kolchinsky, a former biotech analyst at Lehman Brothers. Since then, RA Capital has grown to become one of the most respected healthcare investment firms in the world, with over $5 billion in assets under management.

The firm's investment strategy is focused on identifying and investing in companies that are developing innovative therapies and technologies that have the potential to transform the healthcare industry. RA Capital's team of experienced analysts and portfolio managers conduct extensive research and due diligence to identify the most promising investment opportunities in the healthcare sector.

RA Capital's portfolio includes a diverse range of companies, from early-stage startups to established biotech and pharmaceutical companies. Some of the notable companies in RA Capital's portfolio include Moderna, a biotech company that is developing a COVID-19 vaccine, and Intellia Therapeutics, a gene editing company that is developing therapies for genetic diseases.

Peter Kolchinsky, the founder and CEO of RA Capital, is a well-respected figure in the healthcare investment community. He is a frequent speaker at industry conferences and has authored several books on biotech investing. Other key members of RA Capital's management team include Rajeev Shah, the firm's COO, and Derek DiRocco, the Chief Investment Officer.

Overall, RA Capital Management is a highly respected investment firm that has a proven track record of identifying and investing in innovative healthcare companies. Investors who are interested in the healthcare sector may want to consider RA Capital as a potential investment opportunity.

It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.

Top long-term holdings
NameQuarters ownedLatest quarter ownedMax weighting
ASCENDIS PHARMA A/S - ADR35Q3 202325.5%
WAVE LIFE SCIENCES PTE LTD32Q3 202326.3%
TG THERAPEUTICS INC30Q4 20216.3%
ZOGENIX INC26Q4 20219.5%
BIOCRYST PHARMACEUTICALS23Q1 20199.2%
DICERNA PHARMACEUTICALS INC23Q3 20195.8%
RHYTHM PHARMACEUTICALS INC22Q3 20234.4%
ACHILLION PHARMACEUTICALS INC19Q4 201717.2%
KALA PHARMACEUTICALS INC19Q1 20224.4%
SOLID BIOSCIENCES INC19Q3 20226.8%

View RA Capital Management's complete holdings history.

Latest significant ownerships (13-D/G)
RA Capital Management Q3 2021 significant holdings filed using form 13D/G when ownership exceeds 5% of a company's total stock issue.
FiledShares Percentage
ARS Pharmaceuticals, Inc.September 25, 20239,459,6789.9%
CymaBay Therapeutics, Inc.September 22, 20236,940,0006.2%
BELLUS Health Inc.Sold outAugust 14, 202300.0%
Kinnate Biopharma Inc.Sold outAugust 14, 202300.0%
Vor Biopharma Inc.August 11, 202322,780,34333.7%
DICE Therapeutics, Inc.Sold outAugust 09, 202300.0%
Acumen Pharmaceuticals, Inc.July 25, 202314,981,61825.9%
Talaris Therapeutics, Inc.July 06, 20232,333,1755.5%
Aerovate Therapeutics, Inc.June 27, 20238,293,14830.0%
Satsuma Pharmaceuticals, Inc.Sold outJune 12, 202300.0%

View RA Capital Management's complete significant-ownership history.

Latest filings
TypeFiled
SC 13D2024-03-28
32024-03-27
42024-03-27
32024-03-25
42024-03-25
SC 13G2024-03-25
SC 13G2024-03-25
SC 13D/A2024-03-18
SC 13D/A2024-03-11
42024-03-06

View RA Capital Management's complete filings history.

Compare quarters

Issues

The following issues were detected while analyzing the report:

  • The reported total value is incorrect (7216742000.0 != 7216744000.0)

Export RA Capital Management's holdings